Medigen Vaccine Biologics Corporation (6547.TWO)
- Previous Close
49.80 - Open
49.30 - Bid 49.05 x --
- Ask 48.95 x --
- Day's Range
47.85 - 49.40 - 52 Week Range
33.70 - 57.00 - Volume
879,317 - Avg. Volume
2,755,361 - Market Cap (intraday)
16.108B - Beta (5Y Monthly) 1.05
- PE Ratio (TTM)
-- - EPS (TTM)
-0.24 - Earnings Date May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
102.00
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. Medigen Vaccine Biologics Corporation was incorporated in 2012 and is headquartered in Zhubei City, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.
www.medigenvac.comRecent News: 6547.TWO
View MorePerformance Overview: 6547.TWO
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6547.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6547.TWO
View MoreValuation Measures
Market Cap
16.37B
Enterprise Value
14.79B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
27.03
Price/Book (mrq)
4.25
Enterprise Value/Revenue
24.43
Enterprise Value/EBITDA
197.61
Financial Highlights
Profitability and Income Statement
Profit Margin
-13.29%
Return on Assets (ttm)
-1.74%
Return on Equity (ttm)
-2.09%
Revenue (ttm)
605.64M
Net Income Avi to Common (ttm)
-80.47M
Diluted EPS (ttm)
-0.24
Balance Sheet and Cash Flow
Total Cash (mrq)
1.92B
Total Debt/Equity (mrq)
8.80%
Levered Free Cash Flow (ttm)
-81.08M